PT  - JOURNAL ARTICLE
AU  - Paolo Perella
AU  - Mohammad Tabarra
AU  - Ertan Hataysal
AU  - Amir Pournasr
AU  - Ian Renfrew
TI  - Minimising exposure to droplet and aerosolised pathogens: a computational fluid dynamics study
AID  - 10.1101/2020.05.30.20117671
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.30.20117671
4099  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20117671.short
4100  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20117671.full
AB  - Background Hazardous pathogens are spread in either droplets or aerosols produced during aerosol generating procedures (AGP). Adjuncts minimising exposure of healthcare workers to hazardous pathogens released during AGP may be beneficial. We used state-of-the-art Computational Fluid Dynamics modelling to optimise the performance of a custom-designed shield.Methods We modelled airflow patterns and trajectories of particles (size range 1–500µm) emitted during a typical cough using Computational Fluid Dynamics (ANSYS Fluent software), in the presence and absence of a protective shield enclosing the head of a patient. We modelled the effect of different shield designs, suction tube position, and suction flow rate on particle escape from the shield.Results Use of the shield prevented escape of 99.1–100% of particles, which were either trapped on the shield walls (16–21%) or extracted via suction (79–82%). At most, 0.9% particles remained floating inside the shield. Suction flow rates (40–160L min−1) had no effect on the final location of particles in a closed system. Particle removal from within the shield was optimal when a suction catheter was placed vertically next to the head of the patient. Addition of multiple openings in the shield reduced the purging performance from 99% at 160 L min−1 to 67% at 40 L min−1.Conclusion Computational fluid dynamics modelling provides information to guide optimisation of the efficient removal of hazardous pathogens released during AGP from a custom-designed shield. These data are essential to establish before clinical use and/or pragmatic clinical trials.Competing Interest StatementDesigners/Patent holders: PP/IRFunding StatementInnovate UK provided funding for the design and production of the Shield. Arup undertook the study gratisAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NilAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available online. http://www.the-mtc.org/news-items/intubation-shield-supporting-our-frontline-nhs-workers